{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:56:25Z","timestamp":1790855785886,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"MDACC","award":["CA16672-22"],"award-info":[{"award-number":["CA16672-22"]}]},{"name":"NCI","award":["R21-CA74117"],"award-info":[{"award-number":["R21-CA74117"]}]},{"DOI":"10.13039\/100000069","name":"NIAMS","doi-asserted-by":"crossref","award":["K24 CA 86815"],"award-info":[{"award-number":["K24 CA 86815"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.clml.2015.11.010","type":"journal-article","created":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T11:03:22Z","timestamp":1448967802000},"page":"49-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Retrospective Analysis of Prognostic Factors in\u00a0187 Cases of Transformed Mycosis Fungoides"],"prefix":"10.1016","volume":"16","author":[{"given":"Rakhshandra","family":"Talpur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawen","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Gangar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bouthaina S.","family":"Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Duvic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2015.11.010_bib1","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2009-11-251926","article-title":"S\u00e9zary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct behavior","volume":"116","author":"Campbell","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.11.010_bib2","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.11.010_bib3","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1182\/blood.V92.4.1150","article-title":"Transformation of mycosis fungoides\/S\u00e9zary syndrome","volume":"92","author":"Diamandidou","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.11.010_bib4","first-page":"265","article-title":"Transformation of cutaneous T cell lymphoma to large cell lymphoma. A clinicopathologic and immunologic study","volume":"132","author":"Salhany","year":"1988","journal-title":"Am J Pathol"},{"key":"10.1016\/j.clml.2015.11.010_bib5","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1182\/blood-2008-05-154609","article-title":"Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation","volume":"112","author":"Arulogun","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.11.010_bib6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11899-011-0096-8","article-title":"CD30+ neoplasms of the skin","volume":"6","author":"Duvic","year":"2011","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2015.11.010_bib7","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/sj.jid.5700122","article-title":"CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma","volume":"126","author":"Talpur","year":"2006","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.clml.2015.11.010_bib8","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2133.2007.08008.x","article-title":"Transformed mycosis fungoides: clinicopathological features and outcome","volume":"157","author":"Barberio","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clml.2015.11.010_bib9","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.0906-6705.2005.00293.x","article-title":"Apoptosis in CD30-positive lymphoproliferative disorders of the skin","volume":"14","author":"Greisser","year":"2005","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.clml.2015.11.010_bib10","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2214\/AJR.09.3665","article-title":"Characterization of T-cell lymphomas by FDG PET\/CT","volume":"195","author":"Feeney","year":"2010","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.clml.2015.11.010_bib11","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/archderm.142.5.577","article-title":"Staging accuracy in mycosis fungoides and S\u00e9zary syndrome using integrated positron emission tomography and computed tomography","volume":"142","author":"Tsai","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clml.2015.11.010_bib12","first-page":"563","article-title":"Advanced\/aggressive CTCL: improving the efficacy of treatment","volume":"147","author":"Zinzani","year":"2012","journal-title":"G\u00a0Ital Dermatol Venereol"},{"key":"10.1016\/j.clml.2015.11.010_bib13","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1158\/1078-0432.CCR-12-0604","article-title":"Long-term outcomes of 1,263 patients with mycosis fungoides and S\u00e9zary syndrome from 1982 to 2009","volume":"18","author":"Talpur","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2015.11.010_bib14","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous Lymphoma International Consortium study of outcome in advanced stages of mycosis fungoides and S\u00e9zary syndrome: effect of specific prognostic markers on survival and development of a prognostic model","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.11.010_bib15","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1182\/blood.V100.9.3369","article-title":"Clonal heterogeneity in mycosis fungoides and its relationship to clinical course","volume":"100","author":"Vega","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.11.010_bib16","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/modpathol.2009.175","article-title":"Flow cytometric detection of peripheral blood involvement by mycosis fungoides and S\u00e9zary syndrome using T-cell receptor Vbeta chain antibodies and its application in blood staging","volume":"23","author":"Feng","year":"2010","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clml.2015.11.010_bib17","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2009.25.8301","article-title":"Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and S\u00e9zary syndrome","volume":"28","author":"Duvic","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.11.010_bib18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.clml.2015.11.010_bib19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables (with discussion)","volume":"34","author":"Cox","year":"1972","journal-title":"J\u00a0R Stat Soc B"},{"key":"10.1016\/j.clml.2015.11.010_bib20","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-4632.2009.03771.x","article-title":"Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma","volume":"48","author":"Vidullich","year":"2009","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clml.2015.11.010_bib21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3816\/CLM.2006.n.039","article-title":"Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma","volume":"7","author":"Duvic","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.clml.2015.11.010_bib22","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/annonc\/mdt480","article-title":"Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma","volume":"25","author":"Straus","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2015.11.010_bib23","first-page":"377","article-title":"Update on the treatment of cutaneous T-cell lymphoma (CTCL): focus on vorinostat","volume":"1","author":"Duvic","year":"2007","journal-title":"Biologics"},{"key":"10.1016\/j.clml.2015.11.010_bib24","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1158\/1078-0432.CCR-11-3144","article-title":"Romidepsin for cutaneous T-cell lymphoma","volume":"18","author":"Prince","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2015.11.010_bib25","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.clml.2012.01.010","article-title":"Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study","volume":"12","author":"Foss","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2015.11.010_bib26","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/00000421-198410000-00012","article-title":"Combination chemotherapy for mycosis fungoides with cyclophosphamide, vincristine, methotrexate, and prednisone","volume":"7","author":"Case","year":"1984","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clml.2015.11.010_bib27","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1368::AID-CNCR37>3.0.CO;2-8","article-title":"Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma","volume":"86","author":"Akpek","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2015.11.010_bib28","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0190-9622(99)70079-4","article-title":"Prognostic factor analysis in mycosis fungoides\/S\u00e9zary syndrome","volume":"40","author":"Diamandidou","year":"1999","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clml.2015.11.010_bib29","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/PAT.0000000000000166","article-title":"Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors","volume":"46","author":"Pulitzer","year":"2014","journal-title":"Pathology"},{"key":"10.1016\/j.clml.2015.11.010_bib30","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.11.010_bib31","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood.V96.2.685","article-title":"Expression pattern of T cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T cell non-Hodgkin lymphoma","volume":"96","author":"Jones","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.11.010_bib32","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/bjd.12763","article-title":"Quantitation of tumour development correlates with prognosis in tumour stage (stage IIB) mycosis fungoides","volume":"170","author":"Boonk","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clml.2015.11.010_bib33","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1309\/3N7P-J84L-JQ9K-G89R","article-title":"The T cell chemokine receptor CXCR3 is expressed highly in low-grade mycosis fungoides","volume":"115","author":"Lu","year":"2001","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clml.2015.11.010_bib34","first-page":"146","article-title":"The expression of CXCR3 and CD30 in mycosis fungoides","volume":"15","author":"Nikoo","year":"2012","journal-title":"Arch Iran Med"},{"key":"10.1016\/j.clml.2015.11.010_bib35","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.1995.13.6.1343","article-title":"CD30\/Ki-1-positive lymphoproliferative disorders of the skin\u2013clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group","volume":"13","author":"Pauli","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.11.010_bib36","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1182\/blood-2011-08-376319","article-title":"Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases","volume":"119","author":"Benner","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.11.010_bib37","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.11.010_bib38","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.11.010_bib39","doi-asserted-by":"crossref","first-page":"6217","DOI":"10.1158\/1078-0432.CCR-09-0162","article-title":"A\u00a0phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders","volume":"15","author":"Duvic","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2015.11.010_bib40","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a phase II trial of brentuximab vedotin (SGN-35) for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis","volume":"33","author":"Duvic","year":"2015","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015013804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015013804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T20:17:14Z","timestamp":1718223434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265015013804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S2152265015013804"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2015.11.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retrospective Analysis of Prognostic Factors in\u00a0187 Cases of Transformed Mycosis Fungoides","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2015.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}